The sale now is expected to garner $850 million in net proceeds versus the $530 million estimated for the first 10, Smith said. The additional hospitals bring in more revenue. Combined, the dozen hospitals generate about $1.45 billion in annual revenue compared with $1 billion in the first group, he said.
CHS is declining to name the hospitals. However, CFO Larry Cash told analysts on the earnings call that the 12 hospitals and other facilities are packaged in five different deals whereas there were three deals previously for the 10. One of the earlier deals fell through, Cash said.
Smith said CHS expects to complete the transactions this year. The hospitals for sale are generally underperforming, contributing single digit EBITDA margins.
Cash said CHS has made a major push to improve performance at all of its hospitals but especially at the more than 60 acquired in early 2014 as part of its $3.9 billion purchase of Health Management Associates.
Some of those hospitals were divested in the April spin-off of Quorum Health Corp., a group of 38 rural hospitals that CHS determined would operate better as a separate company.
Cash said of 153 hospitals CHS currently operates, the 61 former HMA hospitals operated by CHS continue to post revenue and earnings below that of CHS's 92 legacy hospitals.
Problems are particularly acute at some of the former HMA hospitals in Florida, which CHS has tried to buttress by recruiting more physicians and putting management attention there, Cash said.
Those efforts notwithstanding, the former 61 former HMA hospitals combined in the second quarter posted 3% declines in revenue, surgeries and admissions, and contributed to CHS's decline in adjusted EBITDA during the quarter, Cash said.
In contrast, CHS's 91 legacy hospitals posted 3% gains in revenue and surgeries in the quarter, with a 1% decline in admissions.
The goodwill baked in the HMA acquisition also was addressed by a $1.4 billion non-cash write-down against hospital goodwill that CHS booked in the quarter. Goodwill is the intangible value that a company pays on an acquisition above the tangible value of the assets purchased.
Excluding about $1.6 billion in one-time adjustments, adjusted EBITDA in the second quarter fell to $563 million compared with $769 million in the year-earlier quarter.
Revenue also declined by 6% to $4.6 billion.